GlassScriptPhysician profile
Roxanna B Arakozie
NPI 1538528690
$11,338.48
in general payments reported to CMS, 2019-2025
21 companies · $2,864 in 2025
The $2,864 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,240 · 2022: $2,075 · 2023: $2,282 · 2024: $2,877 · 2025: $2,864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,369 · Education: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,368.93 |
| Education | $654.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,261.04 | 2021-2025 | Tremfya, Remicade, Stelara |
| Abbvie INC. | $2,967.28 | 2021-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $1,516.42 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $991.17 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $741.72 | 2021-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $269.84 | 2023-2025 | Siliq, Jublia |
| Novartis Pharmaceuticals Corporation | $261.23 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $247.09 | 2023-2025 | Zoryve |
| Ucb, INC. | $215.68 | 2025 | Bimzelx |
| Amgen INC. | $143.92 | 2024-2025 | Otezla, Otezla |
| Blueprint Medicines Corporation | $109.21 | 2024 | Ayvakit |
| Pfizer INC. | $94.66 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Novo Nordisk INC | $80.26 | 2022 | |
| Sun Pharmaceutical Industries INC. | $75.97 | 2023-2025 | Absorica Ld, Winlevi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $68.98 | 2021-2025 | Nemluvio |
| Incyte Corporation | $67.39 | 2023-2024 | Opzelura |
| Leo Pharma INC. | $60.74 | 2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $42.11 | 2024 | Sotyktu |
| Next Science LLC | $21.72 | 2023 | Blastx, Xperience, Surgx |
| Boston Scientific Corporation | $17.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxanna Arakozie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.